GHRS GH Research Corp: Multiplikator Forward P/S

A focus on organic trials without M&A triggered a sharp impulse, and the forward P/S trend confirms this growth. GH Research PLC (GHRS) strengthens its position through high brand authority in psychotherapy and strict financial control by management. The current level is now around , demonstrating the market's readiness to support the revenue valuation of GH Research PLC (GHRS) amid the development of innovative drugs.

GH Research plc - Rega forward marang dodolan GHRS (periode 04.07.2022 - 14.11.2026)

Rincian metrik komprehensif lan analitis GH Research Group (GHRS)

- rega pasar lan target rega analis:

Bagan rega GH Research|GHRS - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Kapitalisasi pasar GH Research Group|GHRS - Nilai Perusahaan Nalika Diakuisisi Penuh

- statistik nilai buku emiten:

Nilai Buku saben Saham GH Research|GHRS - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi marang Aset Bersih ghres.com|GHRS - Nilai Agregat Aset

- rincian utang lan likuiditas:

- rincian asil keuangan lan kelipatan valuasi:

GHRS - Bathi resik|Bathi sing dikarepake GH Research PLC|GHRS - Nilai perusahaan marang bathi resik|Pangali Forward P/E GH Research Corp|GHRS - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA GH Research Group|GHRS - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan GH Research|GHRS - Bathi saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan ghres.com|GHRS - Dinamika bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep GH Research PLC

- statistik dodolan lan pendapatan perusahaan:

GHRS - Pendapatan perusahaan|Prakiraan volume dodolan GH Research|GHRS - Kapitalisasi marang pendapatan|Multiplikator Forward P/S GH Research Group

Analisis wiwitan perusahaan:GHRS (GH Research)

GH Research PLC is developing innovative psychiatric pharmacology within the protected jurisdictions of the EU and US to minimize geopolitical risks. The company's forward P/S valuation translates this potential into figures by comparing market capitalization with expected revenue. This ratio measures the premium for future growth, determining the balance between investment attractiveness and the risk of overpayment. Analyzing the dynamics along this curve allows investors to filter out market noise and assess the business's actual margin of safety.

Analisis perusahaan pesaing

Rasio rega marang prakiraan pendapatan Alkermes ALKS|Avadel Pharmaceuticals PLC (AVDL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|atai Life Sciences Corp - Multiplikator Forward P/S|Prakiraan rega marang pendapatan Mind Medicine Corp (MNMD)|CMPS: Multiplikator Forward P/S|lbpharma.us - Rega forward marang dodolan|Multiplikator forward rega marang pendapatan DRUG|VNDA: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Cybin Inc. (CYBN)|ANRO (Alto Neuroscience Corp) - Rega forward marang dodolan|Multiplikator Forward P/S NRXP (NRx Pharmaceuticals)|Cingulate Inc (CING) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|SILO - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake China Pharma Holdings CPHI|CMND: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Psyence Bio (PBM)|SPRC (SciSparc Ltd) - Multiplikator Forward P/S|Multiplikator Forward P/S seelostherapeutics.com|Rasio rega marang prakiraan pendapatan Virpax Pharmaceuticals (VRPX)|KRTX (Karuna Therapeutics Inc) - Rega forward marang dodolan